Pain management最新文献_第2页

Nutrition care in pain rehabilitation-success and lessons from practice. 疼痛康复中的营养护理——成功与实践经验。

IF 1.5

Pain management Pub Date : 2025-10-01 DOI: 10.1080/17581869.2025.2567836

Huan-Ji Dong, Anna Wahl, Maria Henström Engblom, Marie Löf, Lucy Kocanda, Katherine Brain

引用次数: 0

Academic and societal impact of cancer pain research: a bibliometric and Altmetric Analysis. 癌症疼痛研究的学术和社会影响：文献计量学和替代计量学分析。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-07-18 DOI: 10.1080/17581869.2025.2535270

Özge Özpolat Bulut, Mevlüt Özmen, Faisal Al Ali, Ismael Shaukat, Fatih Bağcıer

{"title":"Academic and societal impact of cancer pain research: a bibliometric and Altmetric Analysis.","authors":"Özge Özpolat Bulut, Mevlüt Özmen, Faisal Al Ali, Ismael Shaukat, Fatih Bağcıer","doi":"10.1080/17581869.2025.2535270","DOIUrl":"10.1080/17581869.2025.2535270","url":null,"abstract":"Background: Cancer-related pain affects quality of life despite advancements in management. Bibliometric and altmetric analyses provide insights into the academic and societal impact of research.Objective: This study analyzed the top 100 most-cited articles on cancer-related pain using bibliometric and altmetric indicators, exploring correlations between altmetric scores, citations per year, and total citations.Methods: A search of the Web of Science Core Collection database was conducted on 2 November 2024, to identify articles related to cancer pain published between 1975 and 2024. The top 100 most-cited articles were selected based on total citation counts. Only English-language articles with full-text access were included. Bibliometric data were collected. Altmetric scores were retrieved using the Altmetric Explorer platform, and correlations were assessed using Spearman's test.Results: The 100 most-cited articles appeared in 35 journals, with PAIN contributing the most (n = 19). Total citations and citations per year showed a strong correlation (r = 0.64), but the correlation between altmetric scores and total citations was weak (r = 0.18).Conclusion: This study highlights the academic and societal impact of cancer pain research. The weak correlation between citations and altmetric scores suggests a need for better dissemination strategies to enhance public engagement.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"693-702"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain. 关节内树脂干扰素，一种有效的TRPV1激动剂，用于治疗骨关节炎疼痛。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-08-08 DOI: 10.1080/17581869.2025.2535271

Michael J Iadarola, Matthew R Sapio, Alexis Nahama, Andrew J Mannes

{"title":"Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain.","authors":"Michael J Iadarola, Matthew R Sapio, Alexis Nahama, Andrew J Mannes","doi":"10.1080/17581869.2025.2535271","DOIUrl":"10.1080/17581869.2025.2535271","url":null,"abstract":"Clinical investigations of resiniferatoxin (RTX) analgesia are currently ongoing for several human pain indications. RTX is an agonist of the TRPV1 receptor cation ion channel which is activated by capsaicin, heat, and inflammatory conditions. RTX injection at peripheral sites of pain generation will produce a chemo-inactivation of local nerve terminals and axons and block the transmission of nociceptive signals to spinal cord. Clinical human studies with RTX to treat osteoarthritis (OA) pain were preceded by extensive animal and cell system testing which revealed mechanisms of action, range of potentially treatable pain problems, and the safety and efficacy of this interventional analgesic agent. The present review concentrates on RTX, but also examines intraarticular (IA) capsaicin, a lower potency TRPV1 agonist, for the same indication. We review studies of RTX in human patients and canine veterinary subjects with OA pain. To date, results of several phase I clinical trials have only been reported in abstract form and these studies, despite their preliminary nature, will be examined herein. The present assessments indicate that RTX has strong therapeutic promise to be an innovative approach to medical management of pain relief in osteoarthritis and may be permissive to beneficial tissue remodeling.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"659-670"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis. 接受药用大麻治疗的慢性非癌性疼痛患者的阿片类药物减少。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-08-11 DOI: 10.1080/17581869.2025.2544511

Philip M Finch, Leanne M Price, Toby J F Price, Michael J Kent, Peter D Drummond

{"title":"Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis.","authors":"Philip M Finch, Leanne M Price, Toby J F Price, Michael J Kent, Peter D Drummond","doi":"10.1080/17581869.2025.2544511","DOIUrl":"10.1080/17581869.2025.2544511","url":null,"abstract":"Introduction: Opioid sparing by co-prescription of cannabinoids may enable patients to reduce their opioid consumption prescribed for chronic benign pain.Methods: One cohort attending a small private pain clinic (N = 102), already taking opioids, was co-prescribed cannabinoids and another cohort (N = 53) attending a separate pain clinic nearby received only opioids. The two groups were studied prospectively for a year before their drug consumption was assessed.Results: At baseline, median opioid consumption was 40 mg/day in both cohorts. Medicinal cannabis was administered daily in an oil formulation usually starting at 2.5 mg/day and was titrated to maximize benefits. At 12 months, the median dose contained 15 mg delta-9-tetrahydrocannabinol and 15 mg cannabidiol. At one-year follow-up, 46 of 102 cases had dropped out compared with only one of 53 controls. Opioid consumption had decreased significantly at one-year follow-up, the final median dose being lower in cases (2.7 mg/day) than controls (42.3 mg/day) (p < 0.05 in an intention-to-treat analysis). Disability and insomnia had also decreased in cases.Conclusion: The introduction of cannabinoids can produce useful reductions in opioid consumption in real-world settings, with additional benefits for disability and insomnia. However, this treatment is tolerated by only a subgroup of patients.Clinical audit registration: https://www.anzctr.org.au/ identifier is ACTRN12621000875808.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"703-711"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late response to anti-CGRP therapy for migraine. 抗cgrp治疗偏头痛的晚期反应。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-08-21 DOI: 10.1080/17581869.2025.2550931

Oreste Marsico, Marta Lioi, Michele Trimboli

{"title":"Late response to anti-CGRP therapy for migraine.","authors":"Oreste Marsico, Marta Lioi, Michele Trimboli","doi":"10.1080/17581869.2025.2550931","DOIUrl":"10.1080/17581869.2025.2550931","url":null,"abstract":"Migraine is a debilitating neurological disorder affecting 1 billion people worldwide. Traditional preventive drugs showed low efficacy and poor tolerability. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptors offer a new efficacious and safe therapeutic option for migraine patients. According to randomized controlled trials, these disease-specific drugs reduce migraine frequency by ≥ 50% within 3 months. However, real-world studies show that some patients require a longer treatment duration (6 or 12 months). This narrative review aimed to investigate the occurrence of late and ultra-late responses to anti-CGRP therapy, exploring their potential mechanisms and clinical significance. A literature search was performed [PubMed, Web of Science and Google Scholar; publications up to July 2025] to identify relevant studies for this narrative review. Across 10 real-world studies, a proportion of patients who did not respond at 3 months achieved a meaningful clinical response at later time points: some between 3 and 6 months (\"late responders\") and others between 6 and 12 months (\"ultra-late responders\"). Around one-third of initial non-responders improved by 6 months, and among those who remained non-responsive at that point, a further proportion benefited by 12 months. The pathophysiological mechanism behind late response is a field of investigation, and the interaction of anti-CGRPs on the process of central desensitization seems to be crucial. Our review underscores the need to extend treatment beyond the typical 3-month period to attain meaningful benefits from anti-CGRP therapies.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"745-751"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined aerobic exercise and photobiomodulation for pain and other symptoms in fibromyalgia: study protocol. 有氧运动和光生物调节联合治疗纤维肌痛的疼痛和其他症状：研究方案

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1080/17581869.2025.2535272

Cristiano Carvalho, Patricia Gabrielli Vassão, Thatiane Izabele Ribeiro Santos, Alice Torres Pontes, Julia Ghraziely Justino de Oliveira, Catharina Marabiza Pinheiro, Maria Eduarda de Sousa Kawabe, Bruna Genari Sena, Carlos Eduardo Pinfildi, Victor Zuniga Dourado, Ricardo Luís Fernandes Guerra, Mariana Arias Avila Vera, Ana Claudia Muniz Renno

引用次数: 0

Delayed adverse skin reaction to transcutaneous electrical nerve stimulation (TENS) electrodes. 经皮神经电刺激（TENS）电极延迟性皮肤不良反应。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-09-03 DOI: 10.1080/17581869.2025.2549238

Mark I Johnson

{"title":"Delayed adverse skin reaction to transcutaneous electrical nerve stimulation (TENS) electrodes.","authors":"Mark I Johnson","doi":"10.1080/17581869.2025.2549238","DOIUrl":"10.1080/17581869.2025.2549238","url":null,"abstract":"A 76-year-old woman developed a delayed allergic reaction to adhesive pads following home use of transcutaneous electrical nerve stimulation (TENS) for pain management after a complex elbow dislocation. This case highlights the potential for delayed hypersensitivity reactions to TENS electrode pads. Although formal allergology testing was not performed, the woman's self-directed observations offered valuable insight. The clinical presentation and timing of symptom onset were more consistent with allergic rather than irritant contact dermatitis. Allergic contact dermatitis from TENS pads is often linked to specific allergens in the adhesive materials. Hypoallergenic alternatives aim to reduce this risk by eliminating or substituting known sensitizers. Interestingly, the reaction on the painful arm - where titanium plates had been surgically implanted - extended beyond the electrode placement, whereas on the unaffected, pain-free leg, it remained localized. This suggests that local tissue conditions may modulate the immune response. This case demonstrates the importance of clinician awareness regarding potential dermatological adverse events associated with TENS therapy and emphasizes the need for patient education, particularly when TENS is administered independently. Further investigation into the interaction between local inflammatory states and immune reactivity may inform safer electrode design and guide clinical recommendations for safe TENS use.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"671-676"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Open-label placebos for low back pain: unresolved challenges and next steps. 下背部疼痛的开放标签安慰剂：未解决的挑战和下一步。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-07-26 DOI: 10.1080/17581869.2025.2539065

Leo Druart, Parker Lay, Charlotte Blease, Nicolas Pinsault, Cosima Locher, Grayson L Baird, Michael H Bernstein

引用次数: 0

Opioid-free anaesthesia as a valuable alternative to opioid-based practices: evidence and future challenges. 无阿片类麻醉作为阿片类药物实践的宝贵替代方案：证据和未来挑战。

IF 1.5

Pain management Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1080/17581869.2025.2542719

Yann Gricourt, Philippe Cuvillon, Patrice Forget

引用次数: 0

Effect of coenzyme Q10 on pain prevention after thoracoscopic surgery: study protocol. 辅酶Q10在胸腔镜手术后疼痛预防中的作用：研究方案。

IF 1.5

Pain management Pub Date : 2025-09-30 DOI: 10.1080/17581869.2025.2567832

Jie Liu, Li Li, Lan Luo, Na Wu, Fang Xu, Chengkun Tao, Jie Chen, He Huang, Guangyou Duan

引用次数: 0